Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

2021229 citationsJournal Articlegreen Open Access

Authors

Luis Rivera · Universidad Autónoma de Santo Domingo

Shibadas Biswal · Takeda (United States)

Xavier Sáez‐Llorens · Secretaría Nacional de Ciencia, Tecnología e Innovación

Humberto Reynales

Eduardo López‐Medina · Universidad del Valle

Charissa Borja-Tabora · Research Institute for Tropical Medicine

Lulu Bravo · University of the Philippines Manila

Abstract

TAK-003 was efficacious against symptomatic dengue over 3 years. Efficacy declined over time but remained robust against hospitalized dengue. A booster dose evaluation is planned.

Topics & Keywords

Mosquito-borne diseases and control Viral Infections and Vectors Dengue and Mosquito Control Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 75, Issue 1, pp. 107-117

DOI: 10.1093/cid/ciab864

Field-Weighted Citation Impact: 30.06